Comparative Efficacy of Tacrolimus 0.1% and Clobetasol Propionate 0.05% in the Treatment of Alopecia Areata
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 70
- 试验地点
- 1
- 主要终点
- The degree of response was assessed on The basis of hair regrowth as excellent, marked, moderate or slight.
研究概览
简要总结
Methodology: The 70 patients of age 20 to 50 years presented to the out-patient department of CMH Abbottabad suffering from alopecia areata were enrolled. The non-probability consecutive sampling technique was used. Patient in group-A applied clobetasol propionate 0.05% twice daily, whereas Group-B applied topical tacrolimus 0.1% twice daily for upto 3 months. The Patients were assessed at baseline, 4th weeks, 8th week and 12th week after treatment of each session. Hair loss was calculated from SALT score at presentation and on follow-up after 3 months. The degree of response was assessed on the basis of hair re-growth as excellent (>75% re-growth), Marked (51-75% re-growth), moderate (26-50% re-growth), or slight (≤25% re-growth). To determine statistical significance χ2-square test, taking p-value <0.05 as significant, was used.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 50 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients age 20 to 50 years
- •Both male and female
- •Duration of illness less than 2 months
- •those who never received any treatment before
排除标准
- •Patients having duration of alopecia greater than 2 months
- •Atypical alopecia areata i.e., Alopecia universalis etc
- •Hypersensitivity history to topical corticosteroids or tacrolimus
- •patients taking any systemic immune suppression
- •pregnancy/lactation
研究组 & 干预措施
Group A applied Clobetasol Propionate 0.05%
Patient in group-A applied clobetasol propionate 0.05% twice daily for upto 03 months.
干预措施: Group A applied topical Clobetasol Propionate (Drug)
Group B applied topical Tacrolimus 0.1%
Group-B applied topical tacrolimus 0.1% twice daily for upto 3 months.
干预措施: Group B applied topical Tacrolimus (Drug)
结局指标
主要结局
The degree of response was assessed on The basis of hair regrowth as excellent, marked, moderate or slight.
时间窗: 6 months
The degree of response was assessed on the basis of hair regrowth as excellent (\>75% regrowth), marked (51-75% regrowth), moderate (26-50% regrowth), or slight (≤25% regrowth)
次要结局
未报告次要终点
研究者
danyal sajjad
Principal investigator
Combined Military Hospital Abbottabad